Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept
A Single Arm, Investigator Initiated Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Injection in Subjects With Exudative Age-related Macular Degeneration Previously Treated With Ranibizumab or Bevacizumab (ASSESS Study)
Sponsor: Regeneron Pharmaceuticals
A PHASE4 clinical study on Exudative Macular Degeneration, this trial is completed. The trial is conducted by Regeneron Pharmaceuticals and has accumulated 11 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE4
-
Dec 2021 — Dec 2022 [monthly]
Completed PHASE4
▶ Show 6 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE4
-
Aug 2018 — Jan 2021 [monthly]
Completed PHASE4
Status: Unknown Status → Completed · Phase: None → PHASE4
-
Jun 2018 — Aug 2018 [monthly]
Unknown Status
-
Apr 2018 — Jun 2018 [monthly]
Unknown Status
Phase: NA → None
-
May 2017 — Apr 2018 [monthly]
Unknown Status NA
Status: Active Not Recruiting → Unknown Status
-
Jan 2017 — May 2017 [monthly]
Active Not Recruiting NA
First recorded
Jun 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Regeneron Pharmaceuticals
- Rishi Singh
For direct contact, visit the study record on ClinicalTrials.gov .